FINWIRES · TerminalLIVE
FINWIRES

ASX Preview: Australian Shares Set to Rise as Oil Surges on Middle East Tensions; Life360 Posts Lower Q1 Earnings, Higher Revenue

By

Australian shares are poised to rise on Tuesday as oil prices surged above $104 a barrel amid escalating Middle East tensions, after US President Donald Trump warned that a fragile Iran ceasefire was "on life support" following stalled negotiations and continued disruption to shipping through the Strait of Hormuz.

Overnight, the S&P 500 and the Dow Jones Industrial Average each rose 0.2%, while the Nasdaq Composite gained 0.1%.

In the macroeconomy, the ANZ-Roy Morgan Australian consumer confidence fell 3.1 points to 64.1 in the week of May 4 to May 10, ANZ reported Tuesday.

Investors are eyeing the release of Westpac consumer confidence and NAB business confidence reports.

In corporate news, Life360 (ASX:360) reported Tuesday first-quarter earnings of $0.03 per share on revenue of $143.1 million, compared with earnings of $0.05 on revenue of $103.6 million a year earlier.

Insurance Australia Group (ASX:IAG) is targeting gross written premiums of over AU$25 billion, a more than 15% return on equity, and high single-digit earnings per share growth per year by 2030.

Australia's benchmark index fell 0.5% or 42.6 points to close at 8,701.80 on Monday.

Related Articles

Asia

Shenzhen LDROBOT Soars 103% in Hong Kong Trading Debut

Shenzhen LDROBOT's (HKG:1236) shares opened 102.9% above their initial public offering price in a stellar Hong Kong debut on Monday morning.The Chinese robotics company opened at HK$53.50 per share, well above the offer price of HK$26.36.

HKG:1236
Asia

Concord Healthcare to Issue HK$68 Million Convertible Bonds to CSPC Pharma Unit

Concord Healthcare (HKG:2453) agreed to issue HK$68 million of convertible bonds to a unit of CSPC Pharmaceutical (HKG:1093), according to a Monday Hong Kong bourse filing.The oncology healthcare service provider said Dragon Merit will subscribe to the 2% convertible bonds due in April 2027.The bonds are convertible into as many as 40 million Hong Kong-listed shares at an initial conversion price of HK$1.70 per share, representing a premium of about 14.1% to the stock's last closing price.Net proceeds of about HK$63.1 million will mainly be used to repay loans and supplement working capital.Concord Healthcare said the investment is expected to deepen cooperation with CSPC Pharmaceutical in the oncology healthcare sector.

HKG:1093HKG:2453
Asia

Alterity Therapeutics Says Peer-Reviewed Study Validates its Approach to Multiple System Atrophy; Shares Fall 9%

Alterity Therapeutics (ASX:ATH) said findings of a study published in the NeuroImage journal support quantitative susceptibility mapping as an objective imaging biomarker to facilitate the earlier diagnosis of multiple system atrophy (MSA), according to a Monday filing with the Australian bourse.Alterity is advancing its ATH434 lead candidate into a phase three program for multiple system atrophy, a neurodegenerative disease that leads to the failure of the autonomic nervous system and impaired movement.The company said it used quantitative susceptibility mapping in a phase two trial in which ATH434 helped improve diagnostic accuracy and provided "objective evidence of target engagement."The peer-reviewed publication validates the company's approach and "reinforces the role of [quantitative susceptibility mapping] as a biomarker for iron-modulating therapies in MSA," Alterity CEO David Stamler said.The company's shares fell 9% in recent Monday trade.

ASX:ATH